Efficacy of Shufeng Jiedu Capsules in the treatment of sepsis: A prospective, randomized, placebo-controlled trial

Liu, Yuqi; Yu, Yun; Dai, Hui; Fei, Aihua

doi:10.1016/j.eujim.2020.101172

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [9] , and have a broad-spectrum antiviral effect in vitro [17] . In addition, SFJD and antibiotic combination therapy can reduce the inflammatory response and improve prognosis for septic patients [18] . SFJD is an eight-herb prescription that Hu Zhang ( Polygoni cuspidati Rhizoma et Radix) is the monarch-ingredient; Ban Lan Gen ( Isatidis Radix) and Lian Qiao ( Forsythiae Fructus) are adjutant-ingredients; Lu Gen ( Phragmitis Rhizoma), Bai Jiang Cao ( Patrinia scabiosifolia Herba), Ma Bian Cao( Verbenae Herba) and Chai Hu( Bupleuri Radix) are assistant-ingredients; Gan Cao( Glycyrrhizae Radix et Rhizoma) is the envoy-ingredient [9] .…”

Section: Introductionmentioning

confidence: 99%

Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools

Xiong

Dong

Lou

et al. 2020

European Journal of Integrative Medicine

View full text Add to dashboard Cite

Introduction The novel coronavirus pneumonia that broke out in 2019 has become a global epidemic. According to the diagnosis and treatment plan issued in China and the existing clinical data, Shufeng Jiedu (SFJD) Capsule can be effectively used in the treatment of COVID-19 patients. This study aimed to explore its mechanism of action by network pharmacology and molecular docking technology. Methods The Chinese Medicine System Pharmacology Analysis Platform (TCMSP), a Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine (BATMAN-TCM), the Encyclopedia of Traditional Chinese Medicine (ETCM) and related literature records were used to search the composition and main active compounds of SFJD, and to screen out the targets of drug components. Disease-associated genes were obtained by the Human Gene Database (GeneCards), the Human Online Mendelian Inheritance Platform (OMIM) and the DisGeNET database, and the co-targeted genes/proteins as targets of both SFJD and COVID-19 were selected by the Comparative Toxicogenomics Database (CTD). Co-targeted genes/proteins were analyzed by STRING, the Database for Annotation, Visualization and Integrated Discovery (DAVID) and Reactome for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment, and predicted by AutoDock for their high-precision docking simulation. In addition, the therapeutic effect for SFJD treatment on COVID-19 was validated by the Chinese medicine anti-novel coronavirus pneumonia drug effect prediction and analysis platform (TCMCOVID). Results Screening resulted in 163 compounds and 463 targeted genes. The PPI core network contains 76 co-targeted proteins. The Reactome pathways were enriched in signaling by interleukins, immune system, etc. Finally, 6 key proteins of TNF, IL-10, IL-2, IL-6, STAT1 and CCL2 were selected and successfully docked with 4 active ingredients of quercetin, luteolin, wogonin and kaempferol. Conclusion SFJD may play a role in the prevention and treatment of COVID-19 through multiple active compounds acting on multiple targets and then multiple pathways.

show abstract

Section: Introductionmentioning

confidence: 99%